Purchase this article with an account.
L.A. Bynoe, J.N. Weiss; Retinal Endovascular Surgery and Intravitreal Kenalog® for Central Vein Occlusion . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3028.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Retinal endovascular surgery (REVS) is a vitrectomy followed by tissue plasminogen activator injection into a branch of the central retinal vein. REVS may promote visual recovery at a rate 8-fold higher than the spontaneous recovery rate in central vein occlusion (CVO). However, cystoid macular edema is a major factor that may limit post-REVS visual recovery. Methods: Forty-six eyes with CVO received intravitreal Kenalog® injection (IVK) following the REVS procedure. Three subgroups were analyzed retrospectively: 1) Only immediate IVK (delivered at the time of REVS; n=30); 2) Only delayed IVK (delivered at least 2 months following REVS; n=10); and 3) Any delayed IVK (group 2 + 6 eyes that also had immediate IVK; n=16). Results: The rates of 3- and 8-line visual recovery for all REVS/IVK cases were 56% and 22% respectively. For subgroup 1, the rates were 50% and 13%; subgroup 2, 70% and 40%; and subgroup 3, 69% and 38% (see Table below). Conclusions: REVS and IVK may promote visual recovery in eyes with CVO. Delayed delivery of IVK appears to increase the rate of visual recovery much more than IVK delivered immediately following REVS. REVS + IVK for CVO View OriginalDownload SlideView OriginalDownload Slide
This PDF is available to Subscribers Only